176 related articles for article (PubMed ID: 30935566)
1. The METABANK score: A clinical tool to predict survival after stereotactic radiotherapy for oligometastatic disease.
Van den Begin R; Engels B; Collen C; de Vin T; Defauw A; Dubaere E; Barbé K; De Ridder M
Radiother Oncol; 2019 Apr; 133():113-119. PubMed ID: 30935566
[TBL] [Abstract][Full Text] [Related]
2. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
[TBL] [Abstract][Full Text] [Related]
3. Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy.
Franzese C; Comito T; Franceschini D; Loi M; Clerici E; Navarria P; De Rose F; Di Brina L; Mancosu P; Reggiori G; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2020 May; 146(5):1227-1234. PubMed ID: 32056005
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy.
Franzese C; Comito T; Toska E; Tozzi A; Clerici E; De Rose F; Franceschini D; Navarria P; Reggiori G; Tomatis S; Scorsetti M
Radiother Oncol; 2019 Apr; 133():220-226. PubMed ID: 30414754
[TBL] [Abstract][Full Text] [Related]
5. Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy.
Sharma A; Duijm M; Oomen-de Hoop E; Aerts JG; Verhoef C; Hoogeman M; Nuyttens JJ
Acta Oncol; 2019 Jan; 58(1):74-80. PubMed ID: 30280633
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
8. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
[TBL] [Abstract][Full Text] [Related]
9. Analyses of local control and survival after stereotactic body radiotherapy for pulmonary oligometastases from colorectal adenocarcinoma.
Yamamoto T; Niibe Y; Matsumoto Y; Onishi H; Aoki M; Nishikawa A; Oh RJ; Shintani T; Yahara K; Ozaki M; Manabe Y; Jingu K
J Radiat Res; 2020 Nov; 61(6):935-944. PubMed ID: 32940330
[TBL] [Abstract][Full Text] [Related]
10. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter.
Thompson R; Cheung P; Chu W; Myrehaug S; Poon I; Sahgal A; Soliman H; Tseng CL; Wong S; Ung Y; Beatriz Kinupe Abrahão A; Erler D; Zhang L; Ko YJ; Chung HT
Radiother Oncol; 2020 Jan; 142():236-245. PubMed ID: 31543287
[TBL] [Abstract][Full Text] [Related]
13. Exploratory Analysis on Overall Survival after Either Surgery or Stereotactic Radiotherapy for Lung Oligometastases from Colorectal Cancer.
Filippi AR; Guerrera F; Badellino S; Ceccarelli M; Castiglione A; Guarneri A; Spadi R; Racca P; Ciccone G; Ricardi U; Ruffini E
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):505-12. PubMed ID: 26899780
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival.
de Vin T; Engels B; Gevaert T; Storme G; De Ridder M
Ann Oncol; 2014 Feb; 25(2):467-71. PubMed ID: 24355488
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study.
Stefanovic M; Calvet G; Pérez-Montero H; Esteve A; Bujalance MV; Navarro-Martín A; Fernández MDA; González FF; Borras SM; Borbalas AL; Fernandez MN; Garau MM; Calduch AL; Edo FG
Clin Transl Oncol; 2023 Jan; 25(1):199-206. PubMed ID: 36068449
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
[TBL] [Abstract][Full Text] [Related]
17. Long term control stereotactic body radiotherapy (SBRT) for oligometastatic colorectal cancer: a single center study.
Gil-Raga M; Meri-Abad M; Safont Aguilera MJ; Hernández Machancoses A; Lobo M; Calabuig-Fariñas S; López Torrecilla J; Herreros Pomares A; Camps Herrero C
Chin Clin Oncol; 2020 Apr; 9(2):13. PubMed ID: 32192350
[TBL] [Abstract][Full Text] [Related]
18. Motion management during SBRT for oligometastatic cancer: Results of a prospective phase II trial.
Van den Begin R; Engels B; Boussaer M; Dhont J; Burghelea M; Depuydt T; Poels K; Collen C; Gevaert T; Verellen D; Storme G; de Mey J; De Ridder M
Radiother Oncol; 2016 Jun; 119(3):519-24. PubMed ID: 27179921
[TBL] [Abstract][Full Text] [Related]
19. Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases.
Yamashita H; Niibe Y; Yamamoto T; Katsui K; Jingu K; Kanazawa S; Terahara A; Nakagawa K
Jpn J Clin Oncol; 2016 Jul; 46(7):687-91. PubMed ID: 27162324
[TBL] [Abstract][Full Text] [Related]
20. Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease.
Tanadini-Lang S; Rieber J; Filippi AR; Fode MM; Streblow J; Adebahr S; Andratschke N; Blanck O; Boda-Heggemann J; Duma M; Eble MJ; Ernst I; Flentje M; Gerum S; Hass P; Henkenberens C; Hildebrandt G; Imhoff D; Kahl H; Klass ND; Krempien R; Lohaus F; Petersen C; Schrade E; Wendt TG; Wittig A; Høyer M; Ricardi U; Sterzing F; Guckenberger M
Radiother Oncol; 2017 May; 123(2):182-188. PubMed ID: 28169042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
